Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals is a biotechnology company focused on antibody therapies, with its strongest political signal being $33.8M in annual doctor payments and a direct holding by a former President valued between $15,001-$50,000.
BusinessWhat REGN does
Regeneron Pharmaceuticals develops and commercializes antibody-based treatments for serious medical conditions, including eye diseases, cancer, and inflammatory disorders. Its revenue is primarily driven by product sales for EYLEA and Dupixent, with significant investment in research and development. The company engages in substantial physician outreach, evidenced by over $33.8M in annual payments to doctors and healthcare entities.
12 months past · 3 months futureREGN activity timeline
Executive Branch ConflictsREGN held by Trump-administration officials
Lifetime Government AwardsREGN federal contracts
REGN doesn't hold direct federal contracts.
Verified via USASpending.gov: $0 reported in direct prime-contract awards. Companies in this position typically sell federal services indirectly through prime contractors and integrators (e.g., Lockheed Martin, Booz Allen, Microsoft Azure) or through commercial channels that don't appear in USASpending data.
Smart Money · 13F HoldingsHedge funds holding REGN
Politicians Trading REGNMembers of Congress with recent REGN positions
Congressional TradesWho in Congress is trading REGN
Corporate Insiders · Form 4What CEOs, CFOs, and directors are doing with their own stock
No Form 4 activity recorded in the last 180 days.
Bills Affecting REGNLive legislation impacting this stock
Political ProfileWhere REGN sits in Washington
[object Object]
STRUCTURAL: Strong committee alignment via Sen. Collins (Appropriations Chair, HELP member) and $150K in lobbying focused on government funding. EVIDENTIARY: Zero corporate insider buys in 180 days (tier F score), but active congressional trading (16 trades in 12 months) and a direct executive branch holding. Net: High regulatory density and structural access are offset by a lack of bullish insider evidence.
Regulatory ExposureThreats & opportunities
Regulatory threats
-
Heightened scrutiny of physician payment programs under the Sunshine ActCenters for Medicare & Medicaid Services (CMS)"`get_political_influence.doctor_payments` shows $33.8M in total payments for 2024."
-
Potential drug pricing legislation impacting revenueCongress, Department of Health and Human Services (HHS)"Recent bill_impacts list shows 8 healthcare bills with estimated revenue impacts ranging from $4.1M to $6.1M."
Regulatory opportunities
-
Funding for coronavirus therapeutics and biodefense initiativesDepartment of Health and Human Services (HHS), Biomedical Advanced Research and Development Authority (BARDA)"`Lobbying filings` show specific issues: 'Coronavirus therapeutic funding; biodefense funding'."
Capitol Hill AlliesChampions & critics
Congressional champions
Congressional critics
- No specific congressional critics identified.
LobbyingWho's hired to advocate for REGN
Live signals + predictions for REGN — for Founders
The free page above gives you the public record. Members see the real-time intelligence layer on top of it:
- Live 7-layer signal scores when Congress trades REGN
- Bill Pass Index v2 odds for every bill on the watch list
- Iron Triangle alerts (committee × donor × trade)
- SEC Form 4 cluster detection (CEO + CFO + director buys)
- Whale-Opportunity expected-value ranking
- Custom watchlist alerts via email + Discord